Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2024-11-26 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于公司第三期限制性股票激励计划部分对象首次授予的第二个解除限售期解除限售股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the unlocking and listing of restricted shares under the company's third restricted stock incentive plan. It includes specifics about the number of shares unlocked, the dates, the conditions met for unlocking, performance criteria, and changes in shareholding structure. It is not a full financial report, audit report, or earnings release. It is also not a general regulatory filing or a report publication announcement since it contains substantive details about share unlocking and stock incentive plan implementation. The content aligns with announcements related to share issue or capital changes, specifically about restricted stock unlocking and listing. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA).
2024-11-26 Chinese
关于公司第三期限制性股票激励计划部分对象预留授予的第一个解除限售期解除限售股份上市流通的提示性公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the unlocking and listing of restricted shares under the company's third restricted stock incentive plan. It details the number of shares being unlocked, the conditions met for unlocking, the dates, and the impact on share capital structure. The document is a formal notice about the lifting of restrictions on stock previously granted under an incentive plan, including board approvals and compliance with regulatory requirements. It does not contain financial statements or detailed financial performance data but focuses on share unlocking and listing information related to stock incentives. This fits the category of Transaction in Own Shares (POS), which covers share repurchase/issuance and related share capital changes involving the company's own shares, including restricted stock plans and their unlocking.
2024-11-26 Chinese
关于人生长激素注射液新增适应症申请获受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the acceptance of a supplementary application for a new indication of a human growth hormone injection by the National Medical Products Administration. It is a regulatory update about a drug approval process, not a financial report, earnings release, or management discussion. The document is short (717 characters) and serves as an official announcement of a regulatory event related to the company's product. It does not contain financial data, management changes, or shareholder information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-25 Chinese
关于回购注销第三期限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the repurchase and cancellation of restricted stock under the company's third restricted stock incentive plan. It details the number of shares to be repurchased, the price, the reasons for repurchase, approvals from the board and supervisory committee, legal opinions, and financial advisor opinions. The document focuses on a specific corporate action related to share repurchase and cancellation of restricted stock incentives, which is a capital structure change. It is not a full financial report, earnings release, or management discussion. It is not a proxy or voting result announcement, nor a regulatory filing or legal proceeding update. The content fits best under the category of Transaction in Own Shares (POS), as it reports the company's buyback and cancellation of its own shares under an incentive plan.
2024-11-21 Chinese
监事会关于公司第三期限制性股票激励计划相关事项的核查意见
Board/Management Information Classification · 95% confidence The document is a supervisory board's verification opinion regarding the company's third restricted stock incentive plan, including approval of stock unlocking conditions and repurchase cancellation of restricted stocks. It references regulatory rules and company articles but does not contain financial statements or detailed financial performance data. The document is relatively short (826 characters) and focuses on governance and stock incentive plan matters rather than financial results or audit. It is not an announcement of a report publication but a formal opinion from the supervisory board. This fits best under Board/Management Information (MANG) as it relates to management decisions and stock incentive governance.
2024-11-21 Chinese
中国国际金融股份有限公司关于安徽安科生物工程（集团）股份有限公司第三期激励计划首次授予部分第二个解除限售期及预留授予部分第一个解除限售期解除限售条件成就及回购注销部分限制性股票相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to Anhui Anke Biotechnology Engineering (Group) Co., Ltd.'s third restricted stock incentive plan. It discusses the achievement of conditions for lifting restrictions on stock and the repurchase and cancellation of some restricted stocks. The document includes detailed financial data, approval procedures, performance assessments, and legal compliance related to the stock incentive plan. It is not a general annual report, earnings release, or a simple announcement but a detailed advisory report on a specific capital incentive plan involving stock restrictions and repurchases. This fits best under the category of Capital/Financing Update (CAP), as it deals with stock incentive plans, stock unlocking, and repurchase activities, which are financing-related matters. The document length (over 10,000 characters) and detailed content confirm it is a full report, not just an announcement or certification.
2024-11-21 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.